Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.45 |
| ▸ | MMP7 | P09237 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 8/20 | 0.42 |
| ▸ | MMP1 | P03956 | 7/20 | 0.42 |
| ▸ | MMP13 | P45452 | 6/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5639161 | 0.96 | MMP7 (0.46) | MMP2ANPEPMMP7ALDH1A1KMT2A | |
| SCHEMBL5636763 | 0.96 | MMP7 (0.46) | MMP2ANPEPMMP7ALDH1A1KMT2A | |
| SCHEMBL5639397 | 0.96 | MMP7 (0.46) | MMP2ANPEPMMP7ALDH1A1KMT2A | |
| SCHEMBL5639102 | 0.96 | MMP7 (0.46) | MMP2ANPEPMMP7ALDH1A1KMT2A | |
| SCHEMBL5637936 | 0.94 | MMP7 (0.43) | MMP2ANPEPMMP7ALDH1A1KMT2A | |
| SCHEMBL5635253 | 0.91 | MMP7 (0.42) | MMP2ANPEPMMP7ALDH1A1KMT2A | |
| SCHEMBL5635248 | 0.91 | MMP7 (0.42) | MMP2ANPEPMMP7ALDH1A1KMT2A | |
| SCHEMBL5637998 | 0.91 | MMP2 (0.44) | MMP2ANPEPMMP7ALDH1A1KMT2A | |
| SCHEMBL5638032 | 0.90 | MMP2 (0.43) | MMP2ANPEPMMP7ALDH1A1KMT2A | |
| SCHEMBL5637339 | 0.89 | MMP3 (0.42) | MMP2MMP7MMP3MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223751-B2 | Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same | KOLON IND. INC. (KR) | 2007-05-29 | — | — | US | disclosed |
| EP-1389204-A4 | NOVEL SULFONAMIDE DERIVATIVES, INTERMEDIATE THEREOF, ITS PREPARATION METHODS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOLON INC (KR) | 2005-03-23 | — | — | EP | disclosed |
| US-20040138206-A1 | Novel sulfonamide derivatives, intermidiate thereof, its preparation methods, and pharmaceutical composition comprising the same | KOLON LIFE SCIENCE, INC. (KR) | 2004-07-15 | — | — | US | disclosed |
| EP-1389204-A1 | NOVEL SULFONAMIDE DERIVATIVES, INTERMEDIATE THEREOF, ITS PREPARATION METHODS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Kolon Ind. Inc. (KR) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002088115-A1 | NOVEL SULFONAMIDE DERIVATIVES, INTERMEDIATE THEREOF, ITS PREPARATION METHODS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOLON IND. INC. (KR) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138206-A1 | Novel sulfonamide derivatives, intermidiate thereof, its preparation methods, and pharmaceutical composition comprising the same | MMP1, MMP7, STS | MMP2 19/4885ANPEP 217/4885MMP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.